Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

17.37 -0.13 (-0.74%)

Delayed Quote Updated: 2:09 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

36 37 Next >

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

June 26, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

June 26, 2025

From The Schall Law Firm

Via Business Wire

SRPT SECURITIES NOTICE: Sarepta Therapeutics, Inc. Investors May Have Been Affected by Fraud - Contact BFA Law if You Suffered Losses

June 26, 2025

Via ACCESS Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

June 26, 2025

Via ACCESS Newswire

Did The FDA Make A Mistake? Sarepta's Elevidys Approval Under Scrutiny ↗

June 25, 2025

FDA is investigating Sarepta's Elevidys after two deaths from liver failure in non-ambulatory DMD patients, raising safety and regulatory concerns.

Via Benzinga

Topics Death

Sarepta Therapeutics Is Already Down 84% This Year. And The Other Shoe Just Dropped. ↗

June 25, 2025

Shares were under pressure again Wednesday, deepening the 84% loss for the year, as the FDA planned the next steps for Elevidys.

Via Investor's Business Daily

Topics Death

Sarepta Stock Slumps After FDA Opens Probe Into Patient Death, Analyst Sounds Alarm ↗

June 25, 2025

H.C. Wainwright reiterated a ‘Sell’ rating on Sarepta on Wednesday with a $10 price target. The firm views the FDA as a potential headwind for Sarepta now.

Via Stocktwits

Topics Artificial Intelligence Death

This Sarepta Therapeutics Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday ↗

June 25, 2025

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

June 25, 2025

Via ACCESS Newswire

Assessing Sarepta Therapeutics: Insights From 38 Financial Analysts ↗

June 25, 2025

Via Benzinga

BFA Law Notifies Sarepta Therapeutics, Inc. (SRPT) Investors that the Company is being Investigated for Securities Fraud - Contact the Firm if You Lost Money

June 25, 2025

Via ACCESS Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

June 24, 2025

Via ACCESS Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

June 23, 2025

From Pomerantz LLP

Via GlobeNewswire

SRPT FRAUD NOTIFICATION: Did Sarepta Therapeutics, Inc. Commit Securities Fraud? Investors are Urged to Contact BFA Law

June 23, 2025

Via ACCESS Newswire

SRPT REVIEW: Sarepta Therapeutics, Inc. is Being Investigated for Securities Fraud After Elevidys Death - Investors Are Urged to Contact BFA Law

June 20, 2025

Via ACCESS Newswire

Analyst Downgrades Sarepta As Elevidys Safety Clouds Future Demand ↗

June 20, 2025

Sarepta shares face pressure after a second Elevidys-linked death and analyst downgrade over safety concerns and lowered revenue prospects.

Via Benzinga

This Sarepta Therapeutics Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday ↗

June 20, 2025

Via Benzinga

The FDA Shake-Up Continues, And Could Impact Genetic Medicines ↗

June 20, 2025

Nicole Verdun and Rachael Anatol were placed on administration leave without explanation.

Via Investor's Business Daily

Topics Government

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

June 20, 2025

Via ACCESS Newswire

2 Growth Stocks with All-Star Potential and 1 to Ignore

June 20, 2025

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s...

Via StockStory

Topics Artificial Intelligence

SRPT INQUIRY NOTICE: Lose Money on Sarepta Therapeutics, Inc.? Contact BFA Law About its Securities Fraud Investigation

June 19, 2025

Via ACCESS Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

June 18, 2025

From Pomerantz LLP

Via GlobeNewswire

Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences

June 18, 2025

After a second patient passed away, Sarepta Therapeutics crashed. Solid Biosciences rose over 10% in response. Wall Street sees big upside in both names.

Via MarketBeat

Topics Earnings

SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm

June 17, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud

SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm

June 17, 2025

Via TheNewswire.com

Topics Fraud

SRPT BREAKING NEWS: Sarepta Therapeutics, Inc. is being Investigated for Securities Fraud after Second Elevidys Death; Investors with Losses are Notified to Contact BFA Law

June 17, 2025

From Bleichmar Fonti & Auld LLP

Via Business Wire

US Stock Futures Tumble After Trump Threatens 'Real End' To Iran's Nuclear Problem: '...Avoid Getting Whipsawed By Noise,' Says Expert ↗

June 17, 2025

U.S. stock futures were trading lower on Tuesday following Monday's advanced. Futures of major benchmark indices were lower in premarket.

Via Benzinga

Topics Government

Market Monitor News June 17 (ROKU, Advanced Micro Devices UP - Sarepta Therapeutics DOWN) ↗

June 17, 2025

Markets rebound on hopes of Iran de-escalation; oil drops, Roku surges on Amazon deal, Fed decision looms.

Via Chartmill

Topics Economy

Dow Surges Over 300 Points As Iran Signals De-Escalation: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone ↗

June 17, 2025

Via Benzinga

Topics Stocks

1 Oversold Stock Primed to Rebound and 2 to Steer Clear Of

June 17, 2025

The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling...

Via StockStory

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

36 37 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.